carislifesciences.com
May 15, 2025, 12:43
The Role of IHC Expanding the List of Potential Targets – Caris Life Sciences
Caris Life Sciences shared a post on LinkedIn:
“Join our upcoming webinar to learn how Caris Life Sciences is advancing cancer care for emerging biomarkers like Claudin 18.2, FGFR2b, and MET.
Discover our innovations in immunohistochemistry and explore our current offerings and upcoming additions.
Register Now.”
“Here is a particularly timely educational webinar from Caris in light of today’s FDA approval in NSCLC targeting MET which requires IHC for patient identification:
Caris has MET IHC available today for our patients and Dr. Bryant will touch on our experience with this biomarker at Caris Life Sciences.”
More posts featuring Caris Life Sciences.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 4, 2025, 17:02
Jun 4, 2025, 16:33
Jun 4, 2025, 16:33
Jun 4, 2025, 15:56
Jun 4, 2025, 14:21
Jun 4, 2025, 13:42